- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05238324
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II
A Phase 1 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-203 in ERT-Treated Adults With Mucopolysaccharidosis Type II (MPS II) (juMPStart Trial)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase 1 study will evaluate the safety and efficacy of HMI-203 gene therapy in adult male participants with MPS II currently being treated with standard-of-care idursulfase ERT or equivalent. Participants will receive a single dose of HMI-203 administered intravenously. There are 3 planned dose cohorts which will consist of 3 participants each.
Entry into the first dose cohort will be separated by a 60-day dosing interval between each participant to allow the Homology Medicines medical monitor to review safety and efficacy data prior to the second and third participants being enrolled. Enrollment of subsequent participants, in cohorts 2 and 3, will be separated by a 21-day dosing interval between each participant for review of safety and efficacy data.
Escalation to the next dose cohort will occur after 21 days of safety, efficacy, and biomarker data have been reviewed by the Homology Medicines independent DMC.
This entire study is comprised of 5 years, with the most frequent follow up visits occurring in the first year.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Homology Medicines
Study Contact Backup
- Name: Tracy McGregor, M.D.
- Phone Number: 781-819-0967
- Email: clinicaltrials@homologymedicines.com
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2E 7Z4
- M.A.G.I.C. Clinic, Ltd.
-
-
-
-
California
-
Oakland, California, United States, 94609
- UCSF Benioff Children's Hospital Oakland
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale Center for Clinical Investigation
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- University of Utah Pediatric Genetic & Metabolism Clinic
-
-
Virginia
-
Fairfax, Virginia, United States, 22030
- Lysosomal and Rare Disorders Research and Treatment Center, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Adult males 18-45 years of age at the time of informed consent
- Has capacity and is able to understand the purpose and risks of the study and is willing, able and committed to comply with all study procedures for the duration of the trial (a total of 5 years after gene therapy administration)
- Diagnosis of MPS II based on historically decreased I2S enzyme activity and elevated urine GAGs and/or presence of hemizygous IDS pathogenic variant
- Kaufman Brief Intelligence Test-Second Edition (KBIT2) score ≥ 80
- Compliance with regular treatments of ERT for MPS II for at least 12 months prior to enrollment
- Clinically stable relative to urinary GAG levels, ambulation, and cardiopulmonary status for 12 months preceding enrollment
Key Exclusion Criteria:
- Multiple sulfatase disorder as determined by abnormal activity of another lysosomal sulfatase
- Unresponsive and/or intolerant to idursulfase treatment
- History of BMT, stem cell transplant, or gene therapy
- Presence of anti-capsid neutralizing antibodies
- ALT or AST > ULN; Total or Direct bilirubin > ULN
- International normalized ratio (INR) >1.2 ULN
- Hematology values below the normal range
- Hemoglobin A1c ≥ 6.5% or fasting glucose ≥126 mg/dL
- Contraindication to corticosteroid or tacrolimus use
- Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study or, in the opinion of the investigator, makes the potential participant unsuitable for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HMI-203 Low Dose Level Cohort 1
|
HMI-203 delivered intravenously
|
Experimental: HMI-203 Intermediate Dose Level Cohort 2
|
HMI-203 delivered intravenously
|
Experimental: HMI-203 High Dose Level Cohort 3
|
HMI-203 delivered intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the incidence and severity of treatment emergent adverse events (TEAEs) after a single dose administration of HMI-203 (at each dose level) in adult participants with MPS II
Time Frame: Baseline through 260 weeks
|
The following events are defined as TEAEs;
|
Baseline through 260 weeks
|
Evaluate the incidence and severity of adverse events of special interest (AESIs) after a single dose administration of HMI-203 (at each dose level) in adult participants with MPS II
Time Frame: Baseline through 260 weeks
|
The following events are defined as AESIs;
|
Baseline through 260 weeks
|
Evaluate the effect of HMI-203 single administration on urinary GAG levels within each dose cohort
Time Frame: Baseline to week 52
|
Single urine sample GAG levels
|
Baseline to week 52
|
Evaluate the effect of HMI-203 single administration on plasma I2S activity within each dose cohort
Time Frame: Baseline to week 52
|
Measure trough I2S plasma activity
|
Baseline to week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline pulmonary function by evaluating spirometry with lung volumes for FEV1 (Forced Expired Volume).
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Baseline; weeks 52, 104, 156, 208, and 260
|
|
Changes from baseline pulmonary function by evaluating spirometry with lung volumes for FVC (Forced Vital Capacity).
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Baseline; weeks 52, 104, 156, 208, and 260
|
|
Changes from baseline pulmonary function by evaluating spirometry with lung volumes for TLC (Total Lung Capacity).
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Baseline; weeks 52, 104, 156, 208, and 260
|
|
Changes from baseline pulmonary function by evaluating spirometry with lung volumes for RV (Residual Volume).
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Baseline; weeks 52, 104, 156, 208, and 260
|
|
Changes from baseline pulmonary function by evaluating spirometry with lung volumes for TV (Tidal Volume all in L).
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Baseline; weeks 52, 104, 156, 208, and 260
|
|
Changes from baseline pulmonary function by evaluating spirometry with lung volumes for FEV1/FVC ratio (Forced Expiry Volume in 1 second/Forced Vital Capacity).
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Baseline; weeks 52, 104, 156, 208, and 260
|
|
Changes from baseline pulmonary function by evaluating spirometry by DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide mL/min/mmHg).
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Baseline; weeks 52, 104, 156, 208, and 260
|
|
Determine immune response to iduronate 2-sulfatase enzyme (I2S)
Time Frame: Baseline; weeks -1, 1, 4, 8, 12, 24, 52, 78, 104, and 260
|
Measurement of anti-I2S antibodies (total and neutralizing)
|
Baseline; weeks -1, 1, 4, 8, 12, 24, 52, 78, 104, and 260
|
Evaluate the long-term effect of HMI-203 single administration on plasma I2S activity and concentration within each dose cohort
Time Frame: week 52 to week 260
|
Measure trough I2S plasma activity and measure trough I2S plasma concentration
|
week 52 to week 260
|
Evaluate the long-term effect of HMI-203 single administration on urinary GAG levels within each dose cohort
Time Frame: week 52 to week 260
|
Single urine sample GAG levels
|
week 52 to week 260
|
Evaluate the effect of HMI-203 on use of ERT
Time Frame: Baseline through week 260
|
Incidence of ERT discontinuation by 52 weeks following HMI-203 administration and among participants who have discontinued ERT by 52 weeks.
Annualized frequency of ERT infusions at weeks 24, 52, 76, 104, 156, 208 and 260.
|
Baseline through week 260
|
Changes from baseline in 6-minute Walk Test (6MWT) performance
Time Frame: Baseline to timepoints between Week 52 to Week 260
|
Change from baseline in mean 6-minute walk test (6MWT)
|
Baseline to timepoints between Week 52 to Week 260
|
Changes from baseline in cardiac mass
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Cardiac mass will be evaluated by performing a transthoracic 2-dimensional echocardiogram.
|
Baseline; weeks 52, 104, 156, 208, and 260
|
Changes from baseline in cardiac function
Time Frame: Baseline; weeks 52, 104, 156, 208, and 260
|
Cardiac function will be evaluated by performing a transthoracic 2-dimensional echocardiogram with doppler flow.
|
Baseline; weeks 52, 104, 156, 208, and 260
|
Change in CSF levels of heparan sulfate
Time Frame: Baseline; weeks 52, 260
|
Measure CSF heparan sulfate
|
Baseline; weeks 52, 260
|
Change in CSF levels of dermatan sulfate
Time Frame: Baseline; weeks 52, 260
|
Measure CSF dermatan sulfate
|
Baseline; weeks 52, 260
|
Change in CSF levels I2S activity and concentration
Time Frame: Baseline; weeks 52, 260
|
Measure CSF I2S activity and concentration
|
Baseline; weeks 52, 260
|
Determine immune response to the HMI-203 delivery capsid by evaluating the incidence of antibodies
Time Frame: Baseline; weeks 52 and 260
|
Measurement of anti-AAVHSC antibodies (total and neutralizing)
|
Baseline; weeks 52 and 260
|
Determine immune response via cytotoxic T-lymphocyte CD8+ (ELISpot)
Time Frame: Baseline; week 52
|
Baseline; week 52
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Connective Tissue Diseases
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Mucopolysaccharidosis II
- Mucopolysaccharidoses
Other Study ID Numbers
- HMI-203-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucopolysaccharidosis II
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedKrabbe Disease | Mucopolysaccharidosis Type II (MPS II) | Mucopolysaccharidosis Type I (MPS I) | Mucopolysaccharidosis Type III (MPS III) | Mucopolysaccharidosis Type VI (MPS VI)United States
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis Type IV | Mucopolysaccharidosis Type VIIUnited States, Canada
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Brazil
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Canada
-
Lundquist Institute for Biomedical Innovation at...CompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VIUnited States
-
University Hospital HeidelbergCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Coping Behavior | Mucopolysaccharidosis Type III | Behavior DisordersGermany
-
TakedaCompletedMucopolysaccharidosis (MPS)Brazil
-
JCR Pharmaceuticals Co., Ltd.Active, not recruitingMucopolysaccharidosis IIJapan
-
JCR Pharmaceuticals Co., Ltd.Completed
-
Denali Therapeutics Inc.RecruitingMucopolysaccharidosis IIUnited States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Colombia
Clinical Trials on Genetic HMI-203
-
Hope Medicine (Nanjing) Co., LtdRecruitingAndrogenetic AlopeciaChina
-
Homology Medicines, IncTerminatedPhenylketonuria | Phenylketonurias | PAH DeficiencyUnited States
-
Hope Medicine (Nanjing) Co., LtdCompleted
-
Chulalongkorn UniversityUnknownHealth Care Quality, Access, and Evaluation | Insurance, Health
-
ICM Co. Ltd.Not yet recruiting
-
ICM Co. Ltd.Enrolling by invitationOsteoarthritis, KneeAustralia
-
Orion Corporation, Orion PharmaCompletedSolid TumoursFrance, Finland, Spain, Italy, Denmark, United Kingdom
-
Columbia UniversityNational Cancer Institute (NCI)Recruiting
-
Orion Corporation, Orion PharmaQuotient ClinicalCompleted
-
Hope Medicine (Nanjing) Co., LtdRecruitingEndometriosisChina, United States, Poland